However, raloxifene therapy has been linked to an increased risk of venous thromboembolism [6,7], likely due to its estrogenic effects on hepatic coagulation pathways, including significant reductions in plasma antithrombin activity [9], elevated plasma levels of coagulation factors VIII, XI, and XII, and decreased sensitivity to activated protein C in postmenopausal women [10]. The gene discussed is F8; the disease is venous thromboembolism.